The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-08 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
==== 2000s ==== 2000 – First Medical Inc., Amelung GmbH, ARK Scientific 2001 – ISOTEC (produces stable isotopes used in basic research and medical diagnostics) 2004 – Ultrafine (a supplier of contract manufacturing services for drug development), Tetrionics (a producer of high potency and cytotoxic active pharmaceutical ingredients) 2005 – JRH Biosciences, an industrial supplier of cell culture products for the pharmaceutical and biotechnology industries; Proligo Group, a global supplier of genomics research tools 2006 – Beijing Superior Chemicals, Iropharm, Pharmorphix, Advanced Separation Technologies (manufacturer of products for chiral chromatography) 2007 – Epichem acquired to expand capabilities in materials sciences and semiconductor markets; Molecular Medicine BioServices acquired to provide large-scale viral manufacturing capabilities; announced alliance with Sangamo BioSciences to develop zinc finger-based laboratory research reagents 2009 – ChemNavigator 2010 – Cerilliant Corporation, ACE Animals 2011 – Resource Technology Corp, Vetec Quimica Fina 2012 – Research Organics Inc., BioReliance (a toxicology and veterinary diagnostics company); BioReliance had previously been acquired by Invitrogen and subsequently sold to Avista Capital Partners. 2014 – Cell Marque 2015 – Combined with EMD Millipore to make MilliporeSigma.
== Bibliography == Lytle, Charles F.; Meyer, John R. (May 21, 2004). General Zoology Laboratory Guide (Fourteenth ed.). New York: McGraw-Hill. ISBN 978-0-07-234900-9. Müller, Werner E.G. (February 2003). "The Origin of Metazoan Complexity: Porifera as Integrated Animals". Integrative and Comparative Biology. 43 (1): 3–10. CiteSeerX 10.1.1.333.3174. doi:10.1093/icb/43.1.3. JSTOR 3884834. PMID 21680404. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help)
Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class used for the treatment of major depressive disorder, anxiety, obsessive–compulsive disorder (OCD), panic disorder, premenstrual dysphoric disorder, and bulimia nervosa. It is also approved for treatment of major depressive disorder in adolescents and children eight years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth. Common side effects of fluoxetine include loss of appetite, nausea, diarrhea, headache, trouble sleeping, dry mouth, and sexual dysfunction. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction. Serious side effects include serotonin syndrome, mania, seizures, an increased risk of suicidal behavior, and an increased risk of bleeding. Fluoxetine was invented by Eli Lilly and Company in 1972. Eli Lilly filed a new drug application for the US Food and Drug Administration in 1974, which was accepted in 1977. It subsequently entered medical use in 1986. It is on the World Health Organization's List of Essential Medicines and is available as a generic medication. In 2023, it was the eighteenth most commonly prescribed medication in the United States and the fourth most common antidepressant, with more than 27 million prescriptions.
After escaping in the present, he seeks out his ex-girlfriend Myra and pilots a ninja-themed Kaijuki called Shinobi Shadow (シノビシャドー, Shinobi Shadō) to stop the Dekarangers, who destroy the Kaijuki with Dekaranger Robo before deleting Sheik with the D-Bazooka. Sheik is voiced by Hideaki Kusaka (日下 秀昭, Kusaka Hideaki). Bileezian Vino (ビリーザ星人ヴィーノ, Birīza Seijin Vīno): An old academy friend of Hoji's from Planet Bileez who retired from S.P.D. out of disenchantment, was lured into a criminal lifestyle by the money he earned from his skills, became a mercenary, reconfigured his body into a monstrous form, and assumed the identity of Gigandes (ギガンテス, Gigantesu) to commit indiscriminate mass murder. In the present, he is hired by Ben G and Agent Abrella to assassinate Kruger and retrieve information on the Deka Base, respectively. Vino succeeds in the latter task before he enlarges himself and is deleted by Dekaranger Robo. Vino is voiced by Naoya Gomoto (郷本 直也, Gōmoto Naoya), who also portrays his original form. Kajimerian Ben G (カジメリ星人ベン・G, Kajimeri Seijin Ben G): A criminal from Planet Kajimeri who was charged with mass-murder and swore revenge on Kruger, following a near-death experience amidst a chase between them that turned the former into a cyborg. As part of his revenge, Ben G tasks a Batsuroid with piloting a drill-themed Kaijuki called Terrible Terror (テリブルテーラー, Teriburu Tērā) to distract the Dekarangers while he infiltrates the Deka Base and kidnaps Swan Shiratori. Terrible Terror is destroyed by Dekaranger Robo, while Ben G is deleted by Deka Master.
=== European response === In response to Trump's threats, EU leaders promised a firm, EU-wide joint response. European Council president António Costa said the EU will be "very firm in defending international law ... starting within the territory of the European Union's member states". European Commission president Ursula von der Leyen promised an "unflinching, united and proportional" response. Kaja Kallas, the EU's High Representative for Foreign Affairs and Security Policy, said China and Russia "must be having a field day" as a result of Trump's tariffs. The EU Parliament suspended approval of a proposed EU–US trade agreement on 21 January, and substantial retaliatory tariffs against the US were readied. French president Macron described Trump's threats as unacceptable and said that "no intimidation nor threat will influence us, neither in Ukraine, nor in Greenland". Norwegian prime minister Jonas Gahr Støre condemned Trump's threats and wrote that "Norway's position is firm: Greenland is part of the Kingdom of Denmark. Norway fully supports the sovereignty of the Kingdom of Denmark." British prime minister Keir Starmer said Trump's trade war is "completely wrong". Danish prime minister Mette Frederiksen said Europe would not be blackmailed by Trump. A joint statement by Denmark, Finland, France, Germany, the Netherlands, Norway, Sweden and the United Kingdom emphasised the principles of sovereignty and territorial integrity and accused Trump of creating a "dangerous downward spiral" with his threats.
Sources: en.wikipedia.org
== Signs and symptoms == Hypomobility can have varying symptoms depending on age. While adolescents can show symptoms of hypomobility, signs and symptoms become more apparent in individuals older than 40 years. As the cartilage around their joints becomes thinner with time, these individuals have a higher risk of hypomobility. In addition, hypomobility can occur in athletes or highly active individuals when there is not sufficient recovery time. Signs of hypomobility include:
=== Sex differences === Men and women have similar reactions to resistance training with comparable effect sizes for hypertrophy and lower body strength, although some studies have found that women experience a greater relative increase in upper-body strength. Because of their greater starting strength and muscle mass, absolute gains are higher in men. In older adults, women experienced a larger increase in lower-body strength.
A humanized mouse is a genetically modified mouse that has functioning human genes, cells, tissues and/or organs. Humanized mice are commonly used as small animal models in biological and medical research for human therapeutics. A humanized mouse or a humanized mouse model is one that has been xenotransplanted with human cells and/or engineered to express human gene products, so as to be utilized for gaining relevant insights in the in vivo context for understanding of human-specific physiology and pathologies. Several human biological processes have been explored using animal models like rodents and non-human primates. In particular, small animals such as mice are advantageous in such studies owing to their small size, brief reproductive cycle, easy handling and due to the genomic and physiological similarities with humans; moreover, these animals can also be genetically modified easily. Nevertheless, there are several incongruencies of these animal systems with those of humans, especially with regard to the components of the immune system. To overcome these limitations and to realize the full potential of animal models to enable researchers to get a clear picture of the nature and pathogenesis of immune responses mounted against human-specific pathogens, humanized mouse models have been developed. Such mouse models have also become an integral aspect of preclinical biomedical research.
Leukotrienes are synthesized in the cell from arachidonic acid by arachidonate 5-lipoxygenase. The catalytic mechanism involves the insertion of an oxygen moiety at a specific position in the arachidonic acid backbone. The lipoxygenase pathway is active in leukocytes and other immunocompetent cells, including Dendritic cell, mast cells, eosinophils, neutrophils, monocytes, and basophils. When such cells are activated, arachidonic acid is liberated from cell membrane phospholipids by phospholipase A2, and donated by the 5-lipoxygenase-activating protein (FLAP) to 5-lipoxygenase. 5-Lipoxygenase (5-LO) uses FLAP to convert arachidonic acid into 5-hydroperoxyeicosatetraenoic acid (5-HPETE), which spontaneously reduces to 5-hydroxyeicosatetraenoic acid (5-HETE). The enzyme 5-LO acts again on 5-HETE to convert it into leukotriene A4 (LTA4), an unstable epoxide. 5-HETE can be further metabolized to 5-oxo-ETE and 5-oxo-15-hydroxy-ETE, all of which have pro-inflammatory actions similar but not identical to those of LTB4 and mediated not by LTB4 receptors but rather by the OXE receptor (see 5-Hydroxyeicosatetraenoic acid and 5-Oxo-eicosatetraenoic acid). In cells equipped with LTA hydrolase, such as neutrophils and monocytes, LTA4 is converted to the dihydroxy acid leukotriene LTB4, which is a powerful chemoattractant for neutrophils acting at BLT1 and BLT2 receptors on the plasma membrane of these cells. In cells that express LTC4 synthase, such as mast cells and eosinophils, LTA4 is conjugated with the tripeptide glutathione to form the first of the cysteinyl-leukotrienes, LTC4.
== Application as a biochemical tool == One of the main uses of this protein is for removing affinity tags from purified recombinant fusion proteins. The reason for the use of TEV protease as a biochemical tool is its high sequence specificity. This specificity allows for the controlled cleavage of proteins when the preference sequence is inserted into flexible loops. It also makes TEV protease relatively non-toxic in vivo as the recognized sequence scarcely occurs in proteins. Although rational design has had limited success in changing protease specificity, directed evolution has been used to change the preferred residue either before or after the cleavage site. In recent developments, a next-generation TEV protease variant called Numacut has been engineered using a combination of AI-guided rational design, allosteric network analysis, and smart mutagenesis. This variant demonstrates efficient and scarless cleavage at ENLYFQ↓X motifs, where virtually all amino acids (except proline) are tolerated in the P1' position, significantly expanding its biotechnological applicability. However, TEV protease does have limitations as a biochemical tool. It is prone to deactivation by self-cleavage (autolysis), though this can be abolished through a single S219V mutation in the internal cleavage site. The protease expressed alone is also poorly soluble, however several attempts have been made to improve its solubility through directed evolution and computational design.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.